Results 201 to 210 of about 525,774 (351)

Association of nailfold capillaroscopic features with cardiac block and arrhythmias due to systemic sclerosis-related primary heart involvement. [PDF]

Reumatologia
Salimi-Beni M, Azizi L, Mohebi M, Mohtasham N, Kabir A, Poormoghim H.   +5 more
europepmc   +1 more source

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

Clinical Pharmacology &Therapeutics, EarlyView.
Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz, Eric Farber‐Eger, Marwa Tantawy, Neyousha Shahisavandi, Timothy J. Garrett, Samuel M. Rubinstein, Michael G. Fradley, Mohammed E. Alomar, Danny DeAvila, Kenneth H Shain, R. Frank Cornell, Daniel Lenihan, Qing Lu, Quinn S Wells, Rachid C. Baz, Yan Gong   +15 more
wiley   +1 more source

In Endurance Athletes at Risk for Arrhythmias, Screen Early and Gauge Often. [PDF]

J Am Heart Assoc
Lewis NDH, Chung EH.
europepmc   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, EarlyView.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Short-Term Arrhythmia Prediction Using AI Based on Daily Data From Implantable Devices: Multicenter Prospective Observational Study. [PDF]

JMIR Cardio
Fernández Lozano I, Fernández de la Concha J, Ramos Maqueda J, Pérez Castellano N, Salguero Bodes R, García-Fernández FJ, Benezet Mazuecos J, Jiménez Candil J, Datino T, Briongos Figuero S, Paniagua Olmedillas J, Font de la Fuente MN, López-Dóriga Costales J, Paz Fernández S, Copoví Lucas V.   +14 more
europepmc   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

V-A ECMO for refractory malignant arrhythmia and cardiogenic shock following acute hydrofluoric acid burns: a case report and pathophysiology review. [PDF]

Int J Emerg Med
Zhao P, She ZZ, Shi R, Luo MH, Li YP, Zhang ZA, Luo JC.   +6 more
europepmc   +1 more source

How to deal with cardiac arrhythmia as an issue in the high performance horse [PDF]

, 2014
van Loon, Gunther
core   +1 more source

Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias.

Journal of the American College of Cardiology, 2017
M. Vaseghi, P. Barwad, Federico J Malavassi Corrales, H. Tandri, Nilesh Mathuria, Rushil Shah, Julie M Sorg, J. Gima, K. Mandal, Luis C. Saenz Morales, Y. Lokhandwala, K. Shivkumar   +11 more
semanticscholar   +1 more source

The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review

ESC Heart Failure, Volume 12, Issue 2, Page 733-760, April 2025.
Abstract Implantable cardioverter defibrillators (ICDs) reliably prevent death due to life‐threatening arrhythmias; this may become less relevant in people with more severe heart failure who are reaching the end of life (EOL). This review aimed to explore the ICD deactivation process and identify ethical issues, especially around the initiation of ...
Siobhan C. Murray, Claire McNamara, Anna V. Chatzi   +2 more
wiley   +1 more source